Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01367600 · ClinicalTrials.gov registry record · Phase 3
Open-Label Treatment Extension of Protocol MNTX 301
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
NCT01367600: Completed Phase 3 study, sponsored by Bausch Health Americas.
NCT01367600 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 27 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01367600, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.
Primary Outcome
To provide access to continued treatment with MNTX administered SC, to patients who completed Progenics' MNTX 301.
Interventions
- DRUG SC Methylnaltrexone (MNTX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2003-02 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
What the finished NCT01367600 record still lists
NCT01367600 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which SC Methylnaltrexone (MNTX) is the first listed.
NCT01367600 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01367600 about?
NCT01367600 is a clinical study titled "Open-Label Treatment Extension of Protocol MNTX 301". This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.
What is the current status of trial NCT01367600?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2003-02. Estimated completion is 2005-02.
What interventions are being tested in trial NCT01367600?
The interventions under investigation include: SC Methylnaltrexone (MNTX) (DRUG).
Who is sponsoring clinical trial NCT01367600?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01367600's enrollment target sits among peer trials
27 1936th of 2000 higher than 64 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia